Digital Commons Network^™

Public Policy Should Foster Alzheimer’S Treatment Availability: Comment On The Draft Us Medicare Decision To Limit Payment For Aducanumab (Aduhelm™) To Patients Participating In Clinical Trials, Jeffrey L. Cummings

Brain Health Faculty Publications

Aducanumab (AduhelmTM) was approved by the United States (US) Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease on June 7, 2021. Soon after, the approved labeling was adjusted to direct treatment to mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia reflecting the severity of cognitive impairment among participants in the clinical trials that led to the approval (1, 2).

Individuals over age 65 in the US are entitled to have the cost of prescription drugs partially paid by the Center for Medicare and Medicaid Services (CMS; “Medicare”) if they participate in an …